| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.5 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.027 | 0.6 |